EN 简 繁
img img img
QR

Who We Are

Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company that is discovering and developing innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. We are based in both the U.S. and China, having been founded in 2007 in Gaithersburg, Maryland.

Sirnaomics’ proprietary delivery platforms for RNA-based therapeutics are the foundation of our product pipeline. Our polypeptide nanoparticle delivery platform (PNP) is primarily used to administer mRNA vaccines and therapeutics. Our GalNAc delivery platform provides systemic administration for liver-targeting RNAi therapeutics.

Who We Are
Who We Are

Science & Pipeline

The Science of RNAi
Pipeline
Research & Development
Drug Delivery Systems
Clinical Studies
Manufacturing
Media
2022.07.26

Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare
for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

2022.06.21

Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics
based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic:
From Concept to Clinic Symposium

2022.06.16

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

View More
Investor Relations
Announcements & Circulars
Announcements & Circulars
Stock Information
Stock Information
Email Subscription
Email Subscription
View More